Title of study
Cerebral amyloid angioathy: vascular imaging and fluid biomarkers of amyloid deposition
Name of Principal Investigator - Title
Name of Principal Investigator - First name
Name of Principal Investigator - Last name
Address of institution -Institution
Radboudumc, Department of Neurology - 830 TML
Address of institution - Street address
Address of institution - City
Address of institution - Postcode
Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?
Alzheimer's disease and other dementias
Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)
To identify novel biomarkers for Cerebral Amyloid Angiopathy, including body fluid (cerebrospinal fluid, blood) and imaging (MRI) biomarkers.
Q2b. What distinguishes this case-control study from other studies?
The focus on the identification of biomarkers for Cerebral Amyloid Angiopathy (CAA) is unique, but is very relevan since CAA occurs at high frequency in brains of eldely and AD patients and contributes to cognitive impairment.
Q3a. i) Number of publications that involve use of your cohort to date
Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study
Description of novel body fluid and imaging biomarkers for hereditary and sporadic CAA
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:
Q4a. Study criteria: what is the age range of participants at recruitment? To:
Q4b. Study criteria: what are the inclusion criteria?
For CAA patients: Clinical diagnosis based on "Boston criteria". For memory clinic patients: no specific inclusion criteria, apart from availability of both CSF and MRI (T2* or SWI)
Q4c. Study criteria: what are the exclusion criteria?
Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?
Q5b. What is the expected number of control participants?
Q6a. Please describe what measures are used to characterise participants
MRI and clinical / neurological examinations
Q6b. Are there additional measures for participants with the clinical disorder?
Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?
Q7. What is the study design?
Retrospective cohort| Cross sectional survey
Q8. Are your cases matched by
Q9a. Does your study includes a specialised subset of control participants?
Q9b. If your study includes a specialised subset of control participants please describe
cases without history of neurological disease, but with CSF & MRI
Q10a. Is data collection for this study
Data collection ongoing| Data analysis ongoing
Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?
Yes - intend to apply for funding
Q11. Are data collected
Through links to medical records
Q12. Is there a system in place to enable re-contact with patients for future studies?
Q13a. Please give information on data stored in a database (1)
Data summarised in database
Q13a. Please give information on data stored in a database (2)
Q13a. Please give information on data stored in a database (3)
Q13a. Please give information on data stored in a database (4)
Q13a. Please give information on data stored in a database (5)
Please specify language used
Q13b. Please give information on how data is held as individual records
Q14a. Are data available to other groups?
Q14b. If data is available to other groups what is the access policy/mechanisms for access?
Access through collaboration with PI only| Local/ regional access| National access| International access| Access to industry| Access for pilot studies permitted
Q15. What data sharing policy is specified as a condition of use?
Q16a. Are tissues/samples/DNA available to other groups?
Q16b i) If yes, please describe below
Living donors: blood| Living donors: cerebro-spinal fluid
Q16b. ii) In what form are tissues/samples/DNA supplied?
Primary Samples: Stabilised samples (frozen or fixed)
Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?
Q17. Is information on biological characteristics available to other groups?
Types: Case Control Studies
Member States: Netherlands
Diseases: Alzheimer's disease & other dementias
Database Categories: N/A
Database Tags: N/A
Export as PDF